Momenta, Sandoz Get $120 Million Lovenox Settlement Approved

Momenta Pharmaceuticals Inc. and Novartis AG unit Sandoz Inc. got final approval from a Tennessee federal judge for a $120 million settlement of claims that they tricked regulators into incorporating a patent on their blood thinner Lovenox into a drug testing standard.

Judge Waverly D. Crenshaw Jr. gave his blessing May 29 to the agreement, which will hand $40 million to the attorneys representing the class action plaintiffs, after giving it a preliminary nod in January. The deal calls for contributions of $85 million from Sandoz and $35 million from Momenta.

It resolves an antitrust lawsuit accusing the two drugmakers ...